Published: May 19, 2025

As GLP-1 receptor agonists like Ozempic, Wegovy, and Rybelsus gain popularity for weight loss and type 2 diabetes management, concerns arise about their impact on individuals with eating disorders. While some patients report benefits, others experience a resurgence of disordered eating behaviors.(Health)

📉 Potential Benefits for Binge Eating Disorders

GLP-1 medications suppress appetite and reduce cravings, which can alleviate symptoms for individuals with binge eating disorder (BED) or bulimia nervosa. Patients have reported decreased “food noise”—the constant preoccupation with food—leading to improved eating behaviors.(Health)

⚠️ Risks for Restrictive Eating Disorders

Conversely, those with a history of restrictive eating disorders, such as anorexia nervosa, may find that GLP-1 drugs exacerbate their condition. The appetite-suppressing effects can lead to meal skipping, excessive weight loss, and a return to harmful behaviors.

🩺 Expert Recommendations

• Screening: Healthcare providers should thoroughly assess patients for eating disorder histories before prescribing GLP-1 medications.(SunCloud Health)
• Monitoring: Regular follow-ups are essential to detect any resurgence of disordered eating behaviors.
• Integrated Care: Collaboration between medical professionals and mental health specialists can ensure comprehensive patient support.

🌐 Broader Implications

The widespread use of GLP-1 drugs raises questions about societal perceptions of body image and the potential for these medications to inadvertently promote unhealthy weight loss practices.(Monte Nido)

Source: Health.com